Primary myelofibrosis with increased haemoglobin concentration at presentation
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Giovanni Barosi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, P…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Hemoglobins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIRC 5 x 1000 MYNERVA project, UK National Institute of Health Research (NIHR), National Institute for Health and Care Research.
Abstract (Originalsprache)
One hundred of 963 consecutive registrants with primary myelofibrosis (PMF) in the Pavia‐CSM database had haemoglobin concentration at diagnosis ≥160 g/L in females or ≥ 165 g/L in males. These subjects were more often female and younger; had higher white blood cell (WBC) and platelet concentrations; and higher frequency of JAK2 V617F and JAK2 V617F variant allele frequency (VAF) compared with those without increased haemoglobin at diagnosis. They had less active disease defined as smaller spleen, lower plasma lactate dehydrogenase, lower blood CD34‐positive cell concentration and less bone marrow fibrosis. They also had a lower plasma high‐sensitivity C‐reactive protein concentration consistent with less inflammation. These subjects were more likely to evolve towards an increased WBC concentration and had a lower risk of progressing to a myelodepletive phenotype compared with those without increased haemoglobin concentration at diagnosis and longer survival (22 vs. 15 years; p < 0.001). In subjects with increased haemoglobin concentration at diagnosis, age >50 years and JAK2 V617F VAF > 75% correlated with worse survival. Our findings suggest that PMF with increased haemoglobin concentration at diagnosis is a unique variant characterized by JAK2 V617F ‐driven hyperproliferation with less inflammation. These features impact prognosis and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for the Study of Myelofibrosis, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
- General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
- Biometry and Clinical Epidemiology, Scientific Direction, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
- Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK.
ORCID-Profile: Giovanni Barosi, Margherita Massa, Robert Peter Gale, Vittorio Rosti
Förderung
- AIRC 5 x 1000 MYNERVA project
- UK National Institute of Health Research (NIHR)
- National Institute for Health and Care Research
Zitieren
APA
Barosi, G., Campanelli, R., Catarsi, P., Abbà, C., Carolei, A., Massa, M., De Silvestri, A., Gale, R. P., & Rosti, V. (2025). Primary myelofibrosis with increased haemoglobin concentration at presentation. British Journal of Haematology. https://doi.org/10.1111/bjh.20233
Vancouver
Barosi G, Campanelli R, Catarsi P, Abbà C, Carolei A, Massa M, et al. Primary myelofibrosis with increased haemoglobin concentration at presentation. British Journal of Haematology. 2025. doi:10.1111/bjh.20233
BibTeX
@article{Barosi2025,
author = {Barosi, Giovanni and Campanelli, Rita and Catarsi, Paolo and Abbà, Carlotta and Carolei, Adriana and Massa, Margherita and De Silvestri, Annalisa and Gale, Robert Peter and Rosti, Vittorio},
title = {Primary myelofibrosis with increased haemoglobin concentration at presentation},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20233}
}
EUVIMED